New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
17:17 EDTETRMEnteroMedics files $75M mixed securities shelf
News For ETRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2015
07:08 EDTETRMEnteroMedics' vBloc therapy shows sustained weight loss at 18 months
EnteroMedics announced that 18 month results from the company's ReCharge Clinical Study published in the Journal of Obesity highlights sustained weight loss in patients receiving vBloc Neurometabolic Therapy. Results at 18 months from the ReCharge Study demonstrate both the sustainability of weight loss using vBloc Therapy and the safety profile of the device over time. The ReCharge Pivotal Trial is a randomized, double-blind, sham-controlled, multicenter pivotal clinical trial of vBloc Neurometabolic Therapy in 239 patients with obesity. At 18 months, the gap between the vBloc Therapy Group and the Sham group widened, with the vBloc Therapy group sustaining their weight loss at 23.5% EWL, compared to a significant excess weight regain in the Sham control group which had dropped to 10.2% EWL at the same time point. The safety profile of vBloc Therapy remained favorable at 18 months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use